Triple-Drug cocktail targets Hard-to-Treat cancers
NCT ID NCT03842228
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patients with specific genetic mutations in their tumors are eligible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Keck Medical Center of USC Pasadena
Pasadena, California, 91105, United States
-
Keck Medicine of USC Buena Park
Buena Park, California, 90621, United States
-
Keck Medicine of USC Koreatown
Los Angeles, California, 90020, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California, 92663, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229, United States
-
University of Texas Medical Branch
Galveston, Texas, 77555-0565, United States
-
University of Texas at Austin
Austin, Texas, 78712, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Copanlisib, olaparib, and durvalumab
What this could lead to
If this works, it could point toward a new treatment option for people with advanced solid tumors that have specific genetic mutations.
What could go wrong
This is a very early (Phase 1) and small trial (39 people), so it's mainly checking safety and dosing. The combination may cause significant side effects and may not shrink tumors in most patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.